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MyogenicmicroRNAs (myomiRs) that are specifically
expressed in cardiac and skeletal muscle are highly
relevant to myogenic development and diseases.
Discovery and elucidation of unknown myomiRs-
involved regulatory pathways in muscle cells are
important, but challenging due to the lack of proper
molecular tools. We report here a miR-221/222-
myoD-myomiRs regulatory pathway revealed by
using a small-molecule probe that selectively inhibits
myomiRs including miR-1, miR-133a, and miR-206.
The small-molecule inhibitor screened from lucif-
erase assay systems was found to inhibit myomiRs
and differentiation of C2C12 cells. Using the small
molecule as a probe, we found that the transcrip-
tional factor myoD, which is upstream of myomiRs,
was further regulated by miR-221/222. This miR-
221/222-myoD-myomiRs regulatory pathway was
confirmed by over-expressing or knockdown miR-
221/222 in muscle cells, which respectively led to
the inhibition or enhancement of myoD protein
expression and subsequent downregulation or upre-
gulation of myomiR expression.
INTRODUCTION
MicroRNAs (miRNAs) are a novel class of small noncoding RNAs
that recently emerged as important endogenous gene regulators
(He and Hannon, 2004). Typically, miRNAs function by binding to
the 30 UTR of target mRNAs, leading to repressed translation
or mRNA degradation. Through posttranscriptional regulation,
miRNAs were estimated to target more than 30% of human
genome (Lewis et al., 2005), and consequently are involved in
diverse biological processes, including proliferation, differentia-
tion, apoptosis, and immune responses (Ebert and Sharp, 2012;
Hoefig and Heissmeyer, 2008). Aberrant expression or function
of miRNAs has been reported to be closely related to the occur-
rence and development of many human diseases (Croce, 2009;
Sullivan and Ganem, 2005).Chemistry & Biology 21, 1265–1Myogenic miRNAs (myomiRs) including miR-1, miR-133a, and
miR-206 are highly enriched in cardiac and skeletal muscle,
which were implicated in muscle and heart development or dis-
ease through regulation of key genes controlling myogenesis
(Callis et al., 2007; Thum et al., 2008; Yang et al., 2007). More-
over, recent studies also found that miR-133a was involved in
brown fat differentiation from myogenic factor 5 (Myf5)-positive
myoblastic lineage and white adipose lineage (Kornfeld and
Bru¨ning, 2012), indicating myomiRs may also play important
roles in obesity and other metabolic diseases. Discovery and
elucidation of unknownmyomiRs-mediated cellular signal trans-
duction pathways remain to be important, but challenging due to
the lack of proper molecular tools.
Chemical biology methods using small molecules that
possess specific biological activity as probes have demon-
strated great potentials in revealing unknown signaling pathways
(Schneider-Poetsch et al., 2010; Schreiber, 2005; Sun et al.,
2012). In recent years, several types of small-molecule modifiers
of endogenous miRNAs have been identified by us and others
(Bose et al., 2012; Chen et al., 2012; Gumireddy et al., 2008; Li
et al., 2014; Shan et al., 2008; Tan et al., 2013; Young et al.,
2010), including small molecules that selectively inhibit the
liver-specific miR-122 (Young et al., 2010) or the cancer-related
miR-21 (Bose et al., 2012; Gumireddy et al., 2008). A small mole-
cule discovered by Jin et al. recently successfully identified a
novel signaling pathway involved in miRNA biogenesis (Li
et al., 2012), highlighting the potential of small-molecule modi-
fiers of miRNAs as molecular tools for the elucidation of
miRNA-involved regulatory pathway. From a special selection
of small molecules obtained from organic photoreactions, we
have found a series of active molecules with significant inhibition
on the muscle-specific miR-1 in C2C12 cells (Tan et al., 2013).
Here we report the chemical biological work using one of the
active compounds as probe to investigate myomiR-involved
cellular regulatory pathway in C2C12 cells.
RESULTS AND DISCUSSION
Figure 1A showed the chemical structure of the small-molecule
inhibitor 1 that has been found to inhibit miR-1 in differentiated
C2C12 cells (Tan et al., 2013). During treatment of C2C12 cells
with compound 1, we observed obvious morphology change
of the cells in differentiation medium. Normally C2C12 cells270, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1265
Figure 1. Compound 1 Inhibits Differentia-
tion of C2C12
(A) Chemical structure of compound 1.
(B) qRT-PCR analysis of mRNA levels of
proliferation and differentiation marker genes
in C2C12 cells upon treatment of compound 1
(10 mM) for 48 hr in differentiation medium.
Data are shown as mean ± SD (n = 3). *p < 0.05,
**p < 0.01.
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culture medium and upon induced differentiation the cells
become long multinucleated myotubes. Upon treatment with
compound 1, C2C12 cells stayed in a relative tranquil state
without obvious proliferation, differentiation, or apoptosis
behavior (Figure S1 available online). Flow cytometry analysis
of C2C12 cells treated with or without compound 1 also sug-
gested that compound 1 indeed inhibited the differentiation of
C2C12 cells (Figure S2). Further real-time quantitative (qRT)-
PCR quantification of proliferation and differentiation markers
in C2C12 cells with or without treatment of compound 1 showed
that differentiation markers including muscle creatine kinase
(MCK), myosin heavy chain (MHC), and myoGenin were signifi-
cantly downregulated in cells treated by compound 1, while
the proliferation marker proliferating cell nuclear antigen
(PCNA) did not respond to compound 1 (Figure 1B).
We checked the effect of compound 1 on other myomiRs
including miR-133a and miR-206. Using C2C12 cells transiently
transfected with luciferase reporters for miR-133a or miR-206,
we were able to tell the effect of compound 1 on endogenous
miR-133a or miR-206 through the change of luciferase signal
from the reporter cells before and after treatment with the com-
pound. Figure 2A showed the relative luciferase signal from cells
transfected with different luciferase reporters upon treatment of
compound 1 at the concentration of 10 mM. After treatment with
compound 1 for 48 hr, relative luciferase signals increased
710-fold from reporter cells for miR-133a andmiR-206 respec-
tively, which is similar to that from the miR-1 reporter cells. In
contrast, using compound 1 to treat cells transfected with lucif-
erase gene-containing empty vectors or reporter cells for other
miRNAs (miR-150, miR-25, miR-214, miR-21, and miR-9) ended
with no significant increase on relative luciferase signal, which
indicated that compound 1 was a selective inhibitor of myomiRs
(Figure 2A).
Dose-dependence curves of compound 1 on its inhibitory
activity toward myomiRs revealed the concentration for 50% of
maximal effect values were 2.5 mM for miR-1 and 5 mM for
miR-206 (Figure 2B). To further validate the specificity as well
as investigate the mode of action of compound 1, expression
levels of different miRNAs in C2C12 cells with and without treat-
ment of compound 1 for 48 hr were quantified by qRT-PCR. The
results showed that expression levels of miR-1, miR-133a, and
miR-206 in compound 1 treated C2C12 cells were 22%, 8%,
and 27% to that in normal C2C12 cells (Figure 2C). In contrast,
expression levels of other miRNAs including miR-150, miR-25,
miR-214, miR-21, and miR-9 were similar in cells with and1266 Chemistry & Biology 21, 1265–1270, October 23, 2014 ª2014 Ewithout treatment of compound 1, which showed there was no
significant difference. These results again confirmed that com-
pound 1 specifically inhibited myomiRs by downregulating the
expression levels of thesemiRNAs in C2C12 cells. Further inves-
tigation on the expression level of primary miR-1 (pri-miR-1),
pri-miR-133a, and pri-miR-206 in C2C12 cells upon treatment
with compound 1 for 48 hr (Figure 2D) showed that the active
compound downregulated myomiRs at transcription level in
C2C12 cells.
The simultaneous downregulation of pri-miRs of myomiRs and
the differentiation markers in C2C12 cells by compound 1 indi-
cated that the compound might target the upstream regulator
that controls the expression of both myomiRs and differentia-
tion-related genes. It has been reported that myomiRs are
related to the regulation of muscle development (Chen et al.,
2006; McCarthy, 2011) and recent evidence suggested that
myoD is the major transcriptional factor of myomiRs (Rao
et al., 2006). In addition, myoD is also an important regulator of
differentiation (Berkes and Tapscott, 2005). Therefore, our initial
hypothesis was that compound 1might inhibit myoD and further
suppress the generation of primary myomiRs and inhibit the
expression of differentiation-related genes. To test this hypothe-
sis, we first compared the mRNA level of myoD in C2C12 cells
with and without treatment by compound 1. qRT-PCR analysis
showed that there was no significant difference between myoD
mRNA levels in C2C12 cells with or without treatment of
compound 1. However, western blot analysis showed that
myoD protein expression level in compound 1 treated cells
was significantly downregulated compared with that in normal
C2C12 cells (Figure 3). The results indicated that compound 1
was able to inhibit the translation of myoD in C2C12 cells without
changing the expression level of myoD mRNA. We next tried to
investigate how the compound suppressed the translation of
myoD protein in C2C12 cells.
MiRNA is known to suppress the translation of its target gene
at posttranscriptional level without altering the amount of mRNA
of the target gene. Since the inhibition of the small molecule on
myoD expression in C2C12 cells was also at posttranscriptional
level, we wondered whether any miRNA-involved regulation on
myoD expression in C2C12 cells was affected by the small mole-
cule. Then we used bioinformatic calculation that has been
commonly used for the estimation of complementarity between
miRNA and 30 UTR region of genes to predict miRNAs with po-
tential binding with myoD (Witkos et al., 2011). Using TargetScan
program (Lewis et al., 2005), we calculated both conserved and
less conserved miRNA-myoD interactions with full pairing inlsevier Ltd All rights reserved
Figure 2. Identification of Compound 1 as a Specific Inhibitor of myomiRs
(A) Relative luciferase signals from cells transfected with empty vector and miRNA reporter vectors upon treatment of compound 1 (10 mM) in differentiation
medium.
(B) Luciferase dose-response curves of compound 1 on miR-1, miR-133a, and miR-206 in C2C12 cells. Relative expression levels of (C) mature miRNAs and (D)
primary miR-1, miR-133a, miR-206 in cells treated with compound 1 (10 mM) and DMSO for 48 hr. Data are shown as mean ± SD (n = 3). *p < 0.05, **p < 0.01.
Figure 3. Inhibition of myoD Gene Expression at Posttranscriptional
Level in Compound 1 Treated Cells
(A) Quantificative RT-PCR analysis of myoD mRNA expression in C2C12 cells
upon treatment of compound 1 (10 mM) for 48 hr in differentiation medium.
(B) Western blotting of myoD protein expression in predifferentiated C2C12
cells after treatment with compound 1 (10 mM) for 48 hr. GAPDH protein was
used as loading control. Data are shown as mean ± SD (n = 3).
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liminary prediction on the interaction between different miRNAs
with myoD gene, we found that a series of miRNAs with rele-
vance to osteogenesis chondrogenesis, smooth muscle devel-
opment, muscular size and dystrophy, or heart diseases were
able to bind with the 30 UTR of myoD gene (Figure S3).
The oncogenic miR-221/222 (Chen et al., 2013; Galardi et al.,
2011) were predicted to target the position 383–389 of myoD
30 UTR, which was unexpected and became a topic of interest
to us. We then calculated the free energy of RNA hybrid
formed by miR-221/222 with myoD. The minimum free energies
were around 26.3 kcal/mol for miR-221-myoD hybrid and
28.1 kcal/mol for miR-222-myoD hybrid, which are well within
the energy range required for authentic miRNA-target pairs. We
also noticed that there are existing evidences that miR-221/222
were related to the differentiation, proliferation, maturation, and
regeneration of skeletal muscle (Cardinali et al., 2009; Greco
et al., 2009; Togliatto et al., 2013). Therefore, we next investi-
gated whether miR-221/222 in C2C12 cells were upstream reg-
ulators of myoD. Using the small molecule 1 as a probe to induce
the acute change of myoD protein expression, we found that the
upregulation of miR-221/222 level was in accompany with the
suppression of myoD protein expression in C2C12 cells treated
with compound 1 (Figure 4A). The results suggested the possibil-
ity of direct suppression of myoD translation by miR-221/222.
To confirm the regulation of miR-221/222 on myoD protein
expression in C2C12 cells, we performed overexpression and
knockdown of miR-221, miR-222, and miR-221/222 in C2C12
cells, respectively (Figure S4). As shown in Figure 4B, transfec-Chemistry & Biology 21, 1265–1tion of C2C12 cells with miRNA mimics of miR-221 and miR-
222 separately or together all led to the significantly decreased
expression of myoD protein according to western blot analysis.
On the other side, myoD protein expression in C2C12 cells trans-
fected with antisense of miR-221 and miR-222 either separately
or together was all upregulated compared with that in normal
C2C12 cells (Figure 4C). These biochemical evidences further
confirmed the regulation of miR-221/222 on myoD gene expres-
sion as revealed by the changes of C2C12 cells upon treatment
with compound 1.270, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1267
Figure 4. Regulation of miR-221/222 on myoD
(A) qRT-PCR analysis of miR-221/222 in C2C12 cells treated with compound 1 (10 mM) for 48 hr in differentiation medium.
(B) Western blot analysis of myoD protein expressions in C2C12 cells transfected with miR-221/222mimics and (C) miR-221/222 antisense after incubated under
differentiation condition for 48 hr. GAPDH was used as loading control.
(D) Direct recognition of themyoD 30-UTR bymiR-221/222. miR-221/222 or NCwere cotransfected with empty vector, reporter vector containingmyoD 30UTR, or
mutant myoD 30UTR into 293T cells. The luciferase signals were determined after 48 hr of transfection. Assay was conducted in triplicates and normalized to NC
control. Data are shown as mean ± SD (n = 3). *p < 0.05, **p < 0.01.
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whether the negative regulation of miR-221/222 on myoD
expression was due to their complementary binding to the
383–389 position at 30 UTR of myoD gene. We constructed a
luciferase reporter plasmid by inserting the entire 30 UTR of
myoD segment to the 30 UTR of luciferase reporter gene. Lucif-
erase reporter plasmid without 30 UTR of myoD (empty vector)
was used as one control. The other control was the luciferase re-
porter plasmid inserted with 30 UTR of myoDmutated at position
383–389 to eliminate its potential binding by miR-221/222. The
constructed reporter plasmids were cotransfected with miR-
221/222 mimics or negative control (NC) oligonucleotide into
293T cells that do not express miR-221/222. Luciferase expres-
sion was then used as the readout as the suppression of gene
expression by miRNA through binding with the 30 UTR of
myoD. As shown in Figure 4D, in cells transfected with empty
vector or the other control plasmid containing mutated binding
sites, the presence ofmiR-221/222 did not show significant influ-
ence on luciferase expression. While in cells transfected with the
reporter plasmid with myoD 30UTR, miR-221/222 significantly
suppressed the expression of luciferase gene. These results
confirmed that miR-221/222 were able to target myoD in
C2C12 cells by binding with its 30 UTR at positions 383–389
and suppress myoD gene expression.
Lastly, to confirm the indirect regulation of miR-221/222 on
myomiRs, expression levels of myomiRs were quantified after
overexpression and knockdown of miR-221, miR-222, and miR-
221/222 in C2C12 cells, respectively. As shown in Figure S5,
myomiR expressions were significantly decreased when C2C12
cells were transfected with miR-221 mimic and miR-222 mimic
separately or together. While transfection with antisense of miR-
221 and miR-222 either separately or together into C2C12 cells
induced significant upregulation of myomiR expressions. These
results further verified the regulationofmiR-221/222onmyomiRs.SIGNIFICANCE
In summary, we reported a regulatory pathway in cells that
was revealed by treatment of C2C12 cells with the selective1268 Chemistry & Biology 21, 1265–1270, October 23, 2014 ª2014 Esmall-molecule inhibitor of myomiRs. The inhibition of
myomiRs by the small molecule was found to be correlated
with the downregulated expression of differentiation
markers. Transcriptional factor myoD was then found to be
suppressed at protein level, but not mRNA level in C2C12
cells treated by the same small molecule, which revealed
the possibility of miRNA regulation on myoD expression.
Using bioinformatic prediction combined with experimental
evidence obtained in the C2C12 cells treated by the small
molecule, we discovered that the oncogenic miR-221/222
were able to target myoD gene through binding with its 30
UTR at positions 383–389 and suppress myoD gene expres-
sion. This newly revealed regulatory pathway was further
confirmed by biochemical evidences obtained by overex-
pression or knockdown of miR-221/222 leading to inhibition
or enhancement ofmyoD protein expression and downregu-
lation or upregulation of myomiR expression inside the
transfected cells. The work reported here demonstrated
the potential applications of small-molecule regulators of
endogenous miRNAs as probes to reveal miRNA-involved
regulatory pathways inside cells. Further work to modify
the small activemoleculewith bio-orthogonal functionalities
for target identification is now underway in our group.
EXPERIMENTAL PROCEDURES
Quantitave RT-PCR Analysis of Mature and Primary miRNA
Expression Level
Total RNA from cells treated with compound 1 and DMSO was isolated using
TRIzol reagent (Invitrogen) according to manufacturer’s protocol. Mature
mmu-miR-1, mmu-miR-133a, mmu-miR-206, mmu-miR-221, and mmu-miR-
222 in differentiated C2C12 cells; hsa-miR-21 in HeLa cells; hsa-miR-25 and
hsa-miR-214 in A549 cells; miR-9 in MCF-7 cells; and miR-150 in RAW267.4
cells were quantified using Taqman miRNA detection assay (Applied Bio-
systems). In general, 1 mg of RNA extracted from cells was used for each reac-
tion. cDNA of interestedmiRNA was synthesized from total RNA using specific
mature miRNA primers (Applied Biosystems) and cDNA Reverse Transcription
Kit (Takara). The reactions were carried out in a thermal cycler for 30 min at
16C, 30 min at 42C, 5 min at 85C, and then held at 4C. Real-time PCR
was performed on Applied Biosystems 7300 Fast Real Time PCR system using
rTaq polymerase (Takara). The reaction was carried out at 95C for 10 min fol-
lowed by 40 cycles of 15 s at 95C and 1 min at 60C. For the primary miRNAlsevier Ltd All rights reserved
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opened by reverse primer in a thermal cycler for 5 min at 85C and then 5 min
at 60C. The pretreated RNA was synthesized into cDNA and then quantified
by qRT-PCR. The thermal procedure for amplification was 95C for 5 min, fol-
lowedby40cycles of 95C for 15 s, and50C for 60 s. The sequences (50 to 30) of
the forward and reverse primers for amplification of primary miR-1, miR-133a,
and miR-206 were included in Table S1. The relative expression level was
calculated using the comparative C1 method. U6 and b-actin were used as in-
ternal controls for quantification of mature and primary miRNAs, respectively.
Quantitative RT-PCR Analysis of Genes mRNA Levels
2 mg of total RNA was reversely transcribed to cDNA using avian myeloblasto-
sis virus reverse transcriptase (Takara) and oligodT (Takara) under thermal pro-
cedure of 42C, 1 hr and 85C, 5 min. 1 ml of cDNA was subjected to PCR
amplification on Applied Biosystem 7300 Real-Time PCR system, using
Evagreen dye (Invitrogen) detection assay. The thermal procedure for amplifi-
cation was 95C, 5 min, followed by 40 cycles of 95C, 30 s; 58C, 30 s; and
72C, 30 s. The relative abundance of mRNA was determined from the Ct
values and beta-actin was used as internal control. The sequences (50 to 30)
of the forward and reverse primers for amplification of differentiation markers
were listed in Table S1.
Overexpression and Knockdown of miR-221 and miR-222
C2C12 cells and 293T cells were seeded on six well plates and transfected the
following day with miR-221/miR-222 mimics or miR-221/miR-222 antisense
(Ribobio) by using Lipo-fectamine 2000 according to manufacturer’s instruc-
tions. The efficiencies of the mimics and antisense were confirmed by qRT-
PCR analyzing miR-221 and miR-222 levels. For miR-221/miR-222 target vali-
dation, the cells were cotransfectedwith empty vector, luciferase-myoD 30UTR
plasmids, or Luciferase-myoD mutant plasmids, and then harvested for lucif-
eraseassayorwesternblottingafter 48hr incubation in correspondingmedium.
For analysis of indirect regulation of miR-221/222 on myomiRs, mature miRNA
expressions ofmyomiRs inC2C12 cellswere quantifiedbyqRT-PCR48 hr after
transfection of miR-221/miR-222 mimics or miR-221/miR-222 antisense.
Statistical Analysis
All of the data are shown as mean ± SD. For each experiment, we repeated at
least three times, and the results are compared using Student’s t test. Signif-
icant difference was considered if p values are less than 0.05.
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